NEO100 Brings Hope to Glioblastoma Patients
Clinical trials and single patient IND (Investigational New Drug) studies play a pivotal role in advancing our understanding of cancer. And it is only through your support of our mission, trials, and medical partnerships that we are able to bring these treatment options to our cherished South Sound community.
NEO100
Currently in a phase 2 clinical trial, NEO100 is a groundbreaking new drug used for the treatment of glioblastoma, a rare and aggressive form of brain cancer with no current FDA-approved treatments. NEO100 is showing promising results–early studies indicate it’s well tolerated and correlates with improved survival, and it recently received the Fast Track and Orphan Disease Designation from the FDA.
How It Works
The brain's most powerful line of defense, the blood-brain barrier, prevents toxins from reaching the brain. However, this same defense network often prevents chemotherapy drugs from reaching the brain as well.
This is where NEO100 (perillyl alcohol) comes in. Unlike conventional chemotherapy agents, this naturally occurring substance, found in essential oils like citrus, penetrates the blood-brain barrier to reach the tumor effectively, acting as a regulator of neurologic pathways associated with tumor cell growth.
Patients self-administer the treatment through a nebulizer in the comfort of their homes four times daily on a 28-day cycle, and visit the clinic once a month for treatment.
Bringing NEO100 to the South Sound
While the NEO100 trial is only available at a few sites nationally, The South Sound Care Foundation in collaboration with ANOVA’s program OneSource, has expanded access to CARE patients through a single patient IND study.
Without a comparable alternative treatment or a clinical trial available locally, we were able to obtain the drug through Compassionate Use at no cost to our patients. Your generous support makes this possible.
PATIENT UPDATES
CARE Patient A.R., now in Cycle 12 of treatment, continues to demonstrate a remarkable response to NEO100 treatment. Her latest scans show no signs of disease progression and her tumor continues to decrease in size. Prior to treatment, her tumor measured 4.26cm x 1.89cm (the size of a lemon) and at the end of cycle 10, it measured 4mm x 11mm (the size of an acorn)! A.R. has experienced a substantial reduction in symptoms, notable improvements in mobility and speech, and has even resumed her yoga practice!
The Results: A.R.s tumor decreased from the size of lemon to the size of an acorn at the end of cycle 10.
Her husband, Tom shares, “Yoga has continued to be a lifeline for her. She went through a difficult period in the fall when tapering her steroid led to mood and energy changes. What really pulled her out of it was resuming her yoga practice. She has a great community at one of the local yoga studios. Prior to her diagnosis, she was on the leaderboard for most classes attended. When she resumed her practice in November, she went to the studio nearly every day for a month, and recently she has been going twice a day and feeling more of her strength and coordination come back as her parietal lobe heals.”
The ability to self-administer daily treatments from home allows A.R. to dedicate time to what matters most–being with Tom, her loved ones, and engaging in activities she loves within her community.
CARE patient, Andrea, is currently undergoing cycle 6 of treatment, and has experienced a substantial reduction in tumor size as well.
As A.R. and Andrea continue their NEO100 treatment and more patients begin their treatment journey, we hope to have more positive updates to share.
CARE patient, Andrea, is currently undergoing cycle 6 of treatment, and has experienced a substantial reduction in tumor size as well.
As A.R. and Andrea continue their NEO100 treatment and more patients begin their treatment journey, we hope to have more positive updates to share.
A.R.
Giving Hope Through Support
With your support, we can continue to provide life-changing treatments for cancer patients in our communities. Your partnership helps individuals like A.R. and Andrea access transformative clinical trials and single patient INDs like NEO100 here in the South Sound, offering hope and innovative treatment options close to home.
